Michigan Institute of Urology | Association Partnerships

January 11, 2022

MIU seizes innovation opportunities presented by dynamic national urology platform caring for nearly one-half million patients.

November 22, 2021

In this interview, Jason M. Hafron, MD, discusses the “buzz” surrounding the meeting and touches on clinical topics including germline and somatic testing, PARP inhibitors, and mitomycin-containing reverse thermal gel (Jelmyto).

November 18, 2021

“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.

November 16, 2021

“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.

November 14, 2021

“The future in bladder cancer [and] prostate cancer is really exploding. The therapeutics are coming faster than we ever thought,” says Jason M. Hafron, MD.

November 13, 2021

“What's great about [Jelmyto] is you can avoid a pretty morbid operation in a typically unhealthy older population, and treat them with localized therapy,” says Jason M. Hafron, MD.